The Altus Patent Umbrella
The ever-evolving Altus Patent Umbrella covers the SmartCelle™, MicroSpheres+™, Flexitab™ and Intellitab™ Technologies that Altus uses to generate differentiated, cost-effective new drug products that stand out in the marketplace.
Altus Patent Umbrella covers all new drug products developed using Altus Technologies, providing continued protection in the marketplace over and above normal exclusivity periods.
Altus Technologies provide protection to an expected 2038 for most drug products.
Altus Patents for NCE and NME
Given the cost of new drug discovery, many new molecules entering clinical development today lack patent protection, shortening their commercial lives or preventing their commercial viability altogether.
Altus Patent Umbrella can provide extended patent coverage for such unapproved molecules, at approval and beyond, reassuring investors of your product’s viability and maximizing its commercial life. Altus Patents can provide protection for drugs approved on the basis of Phase I Pharmacokinetic studies only.
Altus Patents for Value-Added Medicines
The enhancing, repositioning, or repurposing of well-established approved drugs by reformulation as a Value-Added Medicine is seen by many as a cost-effective route for new product approvals. The steady increase in the number of 505(b)(2) applications over recent years is testimony to this.
However, the cost of development using this pathway continues to increase while pricing pressures cut into margins. Altus Patent Umbrella can provide protection after your 5 year (or even 7-year orphan drug) exclusivity, maintaining your market position for longer.